...
search icon
kros-img

Keros Therapeutics Inc Share Price

KROS
NMQ
$16.2
-$0.35
(-2.11%)
1D
Industry: Biotechnology Sector: Health Care

Keros Therapeutics Inc Analyst Forecast

Keros Therapeutics Inc Share Price Chart

Keros Therapeutics Inc Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$504.21M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
10.3654
Volume info-icon
This is the total number of shares traded during the most recent trading day.
468.65K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.84
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$9.12 L
$22.55 H
$16.2

About Keros Therapeutics Inc, Common Stock

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment neuromuscular diseases. The company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts. more

Industry: BiotechnologySector: Health Care

Keros Therapeutics Inc Stock Returns

Time FrameKROSSectorS&P500
1-Week Return-2.29%-0.26%0.42%
1-Month Return-12.1%1.2%1.02%
3-Month Return-3.69%3.86%4.93%
6-Month Return13.84%14.37%7.32%
1-Year Return46.87%6.82%12.16%
3-Year Return-69.78%20.71%71.63%
5-Year Return-75.06%37.78%76.95%
10-Year Return-19.32%135.17%252.5%

Keros Therapeutics Inc Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue2.50M20.10M20.00M151.00K3.55M[{"date":"2020-12-31","value":12.44,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":99.5,"profit":true},{"date":"2023-12-31","value":0.75,"profit":true},{"date":"2024-12-31","value":17.66,"profit":true}]
Cost of Revenue605.00K898.00K1.61M815.00K1.23M[{"date":"2020-12-31","value":37.46,"profit":true},{"date":"2021-12-31","value":55.6,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":50.46,"profit":true},{"date":"2024-12-31","value":76.1,"profit":true}]
Gross Profit(605.00K)20.10M(1.61M)151.00K3.55M[{"date":"2020-12-31","value":-3.01,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-8.03,"profit":false},{"date":"2023-12-31","value":0.75,"profit":true},{"date":"2024-12-31","value":17.66,"profit":true}]
Gross Margin(24.20%)100.00%(8.08%)100.00%100.00%[{"date":"2020-12-31","value":-24.2,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-8.08,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Expenses46.05M76.47M114.79M170.09M214.38M[{"date":"2020-12-31","value":21.48,"profit":true},{"date":"2021-12-31","value":35.67,"profit":true},{"date":"2022-12-31","value":53.54,"profit":true},{"date":"2023-12-31","value":79.34,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(46.66M)(56.37M)(114.79M)(169.94M)(210.83M)[{"date":"2020-12-31","value":-4665700000,"profit":false},{"date":"2021-12-31","value":-5637300000,"profit":false},{"date":"2022-12-31","value":-11479000000,"profit":false},{"date":"2023-12-31","value":-16994100000,"profit":false},{"date":"2024-12-31","value":-21083300000,"profit":false}]
Total Non-Operating Income/Expense1.12M(364.00K)10.11M16.95M23.78M[{"date":"2020-12-31","value":4.7,"profit":true},{"date":"2021-12-31","value":-1.53,"profit":false},{"date":"2022-12-31","value":42.51,"profit":true},{"date":"2023-12-31","value":71.27,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income(45.53M)(56.73M)(104.68M)(152.99M)(187.05M)[{"date":"2020-12-31","value":-4553300000,"profit":false},{"date":"2021-12-31","value":-5673300000,"profit":false},{"date":"2022-12-31","value":-10467900000,"profit":false},{"date":"2023-12-31","value":-15299200000,"profit":false},{"date":"2024-12-31","value":-18705300000,"profit":false}]
Income Taxes(172.00K)2.01M1.00K(206.00K)300.00K[{"date":"2020-12-31","value":-8.55,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":0.05,"profit":true},{"date":"2023-12-31","value":-10.24,"profit":false},{"date":"2024-12-31","value":14.92,"profit":true}]
Income After Taxes(45.36M)(58.74M)(104.68M)(152.79M)(187.35M)[{"date":"2020-12-31","value":-4536100000,"profit":false},{"date":"2021-12-31","value":-5874400000,"profit":false},{"date":"2022-12-31","value":-10468000000,"profit":false},{"date":"2023-12-31","value":-15278600000,"profit":false},{"date":"2024-12-31","value":-18735300000,"profit":false}]
Income From Continuous Operations(45.36M)(58.74M)(104.68M)(152.99M)(187.35M)[{"date":"2020-12-31","value":-4536100000,"profit":false},{"date":"2021-12-31","value":-5874400000,"profit":false},{"date":"2022-12-31","value":-10467900000,"profit":false},{"date":"2023-12-31","value":-15299200000,"profit":false},{"date":"2024-12-31","value":-18735300000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(45.36M)(58.74M)(104.68M)(152.99M)(187.35M)[{"date":"2020-12-31","value":-4536100000,"profit":false},{"date":"2021-12-31","value":-5874400000,"profit":false},{"date":"2022-12-31","value":-10467900000,"profit":false},{"date":"2023-12-31","value":-15299200000,"profit":false},{"date":"2024-12-31","value":-18735300000,"profit":false}]
EPS (Diluted)(6.82)(2.52)(4.15)(5.20)(5.01)[{"date":"2020-12-31","value":-682,"profit":false},{"date":"2021-12-31","value":-252,"profit":false},{"date":"2022-12-31","value":-415,"profit":false},{"date":"2023-12-31","value":-520,"profit":false},{"date":"2024-12-31","value":-501,"profit":false}]

Keros Therapeutics Inc Ratios

Keros Therapeutics Inc Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

KROS
Cash Ratio 28.78
Current Ratio 29.86

Keros Therapeutics Inc Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

KROS
ROA (LTM) 4.40%
ROE (LTM) 10.43%

Keros Therapeutics Inc Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

KROS
Debt Ratio Lower is generally better. Negative is bad. 0.05
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.95

Keros Therapeutics Inc Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

KROS
Trailing PE 10.37
Forward PE 48.78
P/S (TTM) 2.00
P/B 0.72
Price/FCF 158
EV/R 6490.26
EV/Ebitda NM

FAQs

What is Keros Therapeutics Inc share price today?

Keros Therapeutics Inc (KROS) share price today is $16.2

Can Indians buy Keros Therapeutics Inc shares?

Yes, Indians can buy shares of Keros Therapeutics Inc (KROS) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in KROS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Keros Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Keros Therapeutics Inc (KROS) via the Vested app. You can start investing in Keros Therapeutics Inc (KROS) with a minimum investment of $1.

How to invest in Keros Therapeutics Inc shares from India?

You can invest in shares of Keros Therapeutics Inc (KROS) via Vested in three simple steps:

  • Click on Sign Up or Invest in KROS stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Keros Therapeutics Inc shares
What is Keros Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Keros Therapeutics Inc (KROS) is $22.55. The 52-week low price of Keros Therapeutics Inc (KROS) is $9.12.

What is Keros Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Keros Therapeutics Inc (KROS) is 10.3654

What is Keros Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Keros Therapeutics Inc (KROS) is 0.72

What is Keros Therapeutics Inc dividend yield?

The dividend yield of Keros Therapeutics Inc (KROS) is 0.00%

What is the Market Cap of Keros Therapeutics Inc?

The market capitalization of Keros Therapeutics Inc (KROS) is $504.21M

What is Keros Therapeutics Inc's stock symbol?

The stock symbol (or ticker) of Keros Therapeutics Inc is KROS

How Can Investors Use Keros Therapeutics Inc Share Price Data for Long-Term Investment Decisions?

Consider the share price of Keros Therapeutics Inc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Keros Therapeutics Inc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Keros Therapeutics Inc shares for Indian investors?

When investing in Keros Therapeutics Inc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Keros Therapeutics Inc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Keros Therapeutics Inc share price with other stocks in the same sector?

Rather than merely checking the share price of Keros Therapeutics Inc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Keros Therapeutics Inc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top